Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH2 | P25021 | 1/20 | 0.42 |
| ▸ | HRH1 | P35367 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.41 |
| ▸ | THRA | P10827 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | PTGES | O14684 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | PGR | P06401 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6783199 | 0.87 | MEN1 (0.41) | HRH2HRH1MEN1KMT2ASLC6A5 | |
| SCHEMBL6784390 | 0.81 | PTPN1 (0.40) | SLC6A5THRB | |
| SCHEMBL6782805 | 0.79 | HRH2 (0.52) | HRH2HRH1MEN1KMT2A | |
| SCHEMBL6780210 | 0.79 | HRH3 (0.45) | HRH1 | |
| SCHEMBL6783010 | 0.79 | MEN1 (0.40) | HRH2HRH1MEN1KMT2ASLC6A5 | |
| SCHEMBL6785039 | 0.79 | GPR119 (0.46) | — | |
| SCHEMBL6784170 | 0.79 | KMT2A (0.54) | MEN1KMT2A | |
| SCHEMBL6779964 | 0.78 | SMN1; SMN2 (0.53) | HRH2HRH1MEN1KMT2A | |
| SCHEMBL6784626 | 0.78 | PTGES (0.40) | HRH2HRH1MEN1KMT2ASLC6A5 | |
| SCHEMBL6784044 | 0.78 | KMT2A (0.51) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6710060-B2 | 4-hydroxypiperidine derivatives having antiarrhythmic activity | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2004-03-23 | — | — | US | disclosed |
| US-20020188006-A1 | 4-hydroxypiperidine derivatives having antiarrhythmic activity | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2002-12-12 | — | — | US | disclosed |
| EP-1182192-A1 | 4-HYDROXYPIPERIDINE DERIVATIVES HAVING ANTIARRHYTHMIC EFFECT | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2002-02-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020188006-A1 | 4-hydroxypiperidine derivatives having antiarrhythmic activity | SCN5A, RYR2, SCN1B | HRH2 106/4885HRH1 150/4885MEN1 4123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.